Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 74903

Title: Immunotherapy for Nonalcoholic Fatty Liver Disease-related Hepatocellular Carcinoma: Lights and Shadows

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 03725657

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer’s Country/Territory: Japan

Author’s Country/Territory: Italy

Manuscript submission date: 2022-03-18

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-03-19 21:24

Reviewer performed review: 2022-03-20 00:45

Review time: 3 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ Y] Grade A: Excellent</th>
<th>[ ] Grade B: Very good</th>
<th>[ ] Grade C: Good</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade D: Fair</td>
<td>[ ] Grade E: Do not publish</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Language quality</th>
<th>[ Y] Grade A: Priority publishing</th>
<th>[ ] Grade B: Minor language polishing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Conclusion</th>
<th>[ Y] Accept (High priority)</th>
<th>[ ] Accept (General priority)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Minor revision</td>
<td>[ ] Major revision</td>
</tr>
</tbody>
</table>

| Re-review          | [ Y] Yes | [ ] No |
Comments to authors: Authors wrote the manuscript entitled ‘Immunotherapy for Nonalcoholic Fatty Liver Disease-related Hepatocellular Carcinoma: Lights and Shadows’. This manuscript is interesting, but has some concerns and needs revision to be acceptable.

1. Authors cited the reference 94 and discussed the reason why the underlying liver diseases affect the tumor response to immunotherapy. What do you think about relationship between the treatment method (ICI monotherapy, combination with ICI and anti-VEGF agents, and ICI + ICI therapy) and etiology of liver diseases? Please authors discuss it more details.

2. Please authors cited following real-world data concerning the sorafenib (PMID: 34693661) and lenvatinib (PMID: 34515171), and discuss it. In addition, according to the reference 94 (PMID: 34847382), there are significant differences in patient characteristics at baseline between the NASH correlate- and no NASH correlate-patients, leading to possibly significant bias. I believed that citing reference 94 is not suitable for your manuscript.
PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology
Manuscript NO: 74903
Title: Immunotherapy for Nonalcoholic Fatty Liver Disease-related Hepatocellular Carcinoma: Lights and Shadows
Provenance and peer review: Invited Manuscript; Externally peer reviewed
Peer-review model: Single blind
Reviewer’s code: 05387164
Position: Editorial Board
Academic degree: MD, PhD
Professional title: Associate Professor
Reviewer’s Country/Territory: Japan
Author’s Country/Territory: Italy
Manuscript submission date: 2022-03-18
Reviewer chosen by: AI Technique
Reviewer accepted review: 2022-03-19 02:45
Reviewer performed review: 2022-03-21 22:06
Review time: 2 Days and 19 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[Y] Grade B: Very good</th>
<th>[ ] Grade C: Good</th>
<th>[ ] Grade D: Fair</th>
<th>[ ] Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>[ ] Grade A: Priority publishing</td>
<td>[ ] Grade B: Minor language polishing</td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>[ ] Accept (High priority)</td>
<td>[ ] Accept (General priority)</td>
<td>[Y] Minor revision</td>
<td>[ ] Major revision</td>
<td>[ ] Rejection</td>
</tr>
<tr>
<td>Re-review</td>
<td>[Y] Yes</td>
<td>[ ] No</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SPECIFIC COMMENTS TO AUTHORS
Dear author

Thank you for the submission of your article to our journal. I enjoyed your paper and felt your paper should be very informative to many readers except for the problems described below.

1. You should avoid paragraphs with only one sentence, except for paragraphs that state the purpose of the introduction.

2. You should avoid using the same relative pronoun in a sentence such as “which is a M1 phenotype marker which is associated with macrophage-dependent T-cells activation and favorable prognosis in several cancers[50].”

3. P16 English expression “in which PD-L1 is involved limits is usefulness” is strange.